Journal of Molecular Medicine

, Volume 92, Issue 7, pp 697–707

Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

Authors

  • Arjan Gower
    • Georgetown University
  • Yisong Wang
    • Georgetown University
    • Georgetown University
Review

DOI: 10.1007/s00109-014-1165-y

Cite this article as:
Gower, A., Wang, Y. & Giaccone, G. J Mol Med (2014) 92: 697. doi:10.1007/s00109-014-1165-y

Abstract

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. As the genomic classification of lung cancer continues to evolve and as the mechanisms of acquired resistance to targeted therapies become elucidated and more improved target-specific drugs come into sight, the future will see more promising results from the clinic through the development of new therapeutic strategies to overcome, or prevent the development of, resistance for lung cancer patients.

Keywords

Non-small-cell lung cancerOncogenic driversTKIsRTKsAcquired resistance

Copyright information

© Springer-Verlag Berlin Heidelberg 2014